GILD · News · 20261106N

HIV and PrEP Demand Growth

GILEAD SCIENCES, INC. · 2026-11-06 · Importance 59 · Surprise 82

PURPOSE 5 trial results showed nearly twice the one-year persistence among people starting twice-yearly injectable lenacapavir for HIV prevention compared with people starting daily oral emtricitabine/tenofovir disoproxil fumarate (F/TDF). No HIV acquisitions occurred among participants receiving lenacapavir during the 52-week study period. The trial enrolled people in the United Kingdom and France who would benefit from PrEP, highlighting the potential of twice-yearly dosing to address persistence challenges.

Key facts

• In the PURPOSE 5 trial, persistence among people starting twice-yearly injectable lenacapavir for HIV prevention was nearly twice that among people starting daily oral F/TDF. source
• No HIV acquisitions occurred among participants receiving twice-yearly lenacapavir during the 52-week study period. source
• Gilead said PURPOSE 5 findings would be presented at HIV Glasgow 2026. source
• The PURPOSE 5 trial included people in the United Kingdom and France who would benefit from PrEP. source